<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cardiac manifestations of systemic sclerosis (scleroderma)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cardiac manifestations of systemic sclerosis (scleroderma)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Cardiac manifestations of systemic sclerosis (scleroderma)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Monica Mukherjee, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sanjiv Shah, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John Varga, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John S Axford, DSc, MD, FRCP, FRCPCH</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Philip Seo, MD, MHS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan B Yeon, MD, JD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 01, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1657499829"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Cardiac involvement is common in systemic sclerosis (SSc) and is often unrecognized until late in the disease course. The myocardium, pericardium, and conduction system can all be affected. Cardiac manifestations in SSc are variable and can be primary (due to the fibrotic and vascular process or inherent cardiomyocyte abnormalities) or secondary (due to pulmonary arterial hypertension [PAH], interstitial lung disease, cardiac inflammation, or scleroderma renal crisis). Certain medications (eg, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>) used to treat SSc can result in cardiac toxicity.</p><p>This topic will focus on the pathogenesis, epidemiology, clinical manifestations, diagnosis/screening, and management of cardiac involvement in SSc. Other clinical manifestations of SSc are described in detail separately. (See  <a class="medical medical_review" href="/d/html/7539.html" rel="external">"Clinical manifestations and diagnosis of systemic sclerosis (scleroderma) in adults"</a>.)</p><p class="headingAnchor" id="H3107602079"><span class="h1">EPIDEMIOLOGY, ETIOLOGY AND PATHOGENESIS</span><span class="headingEndMark"> — </span>Cardiac involvement is clinically overt in approximately 10 to 30 percent of patients with systemic sclerosis (SSc) [<a href="#rid1">1-3</a>]. Subclinical cardiac involvement, however, has been estimated at &gt;70 percent, depending greatly on clinical suspicion and choice of screening and diagnostic tools utilized for its detection [<a href="#rid4">4</a>]. While primary cardiac involvement can occur in both limited and diffuse cutaneous forms of SSc, manifestations are more severe in those with diffuse disease [<a href="#rid5">5</a>]. There is an elevated risk of cardiac involvement in patients with SSc with rapidly progressing skin disease [<a href="#rid6">6</a>], anti-U3-RNP antibody positivity [<a href="#rid7">7,8</a>], and concomitant skeletal myopathies [<a href="#rid9">9</a>].</p><p>The pathogenesis of SSc cardiac involvement involves recurrent coronary microvascular ischemia and myocardial inflammation leading to ischemic necrosis, reperfusion damage, and myocardial fibrosis  (<a class="graphic graphic_figure graphicRef121514" href="/d/graphic/121514.html" rel="external">figure 1</a>). Pathologic changes in small coronary arteries and arterioles of the subendocardium predispose the myocardium to ischemia-reperfusion injury, which causes apoptosis of the cardiomyocytes and replacement fibrosis [<a href="#rid4">4,10,11</a>]. Myocardial perfusion defects inducible by exposure to cold or during exercise may represent cardiac Raynaud phenomenon [<a href="#rid12">12</a>] due to impairment in coronary flow reserve [<a href="#rid13">13,14</a>]. This has been demonstrated by single photon emission computed tomography (SPECT) imaging [<a href="#rid13">13</a>], cardiac magnetic resonance (CMR) [<a href="#rid15">15-18</a>], and positron emission tomography (PET) imaging [<a href="#rid19">19</a>]. However, a causal relationship between impaired coronary flow reserve and myocardial fibrosis has not been established.</p><p>Adverse myocardial remodeling and fibrosis lead to increased stiffness and diminished compliance of the heart chambers. Clinically, this manifests as left ventricular (LV) diastolic dysfunction, which is highly prevalent in SSc and is associated with increased mortality [<a href="#rid4">4,20-22</a>]. In addition to coronary microvascular dysfunction and fibrosis, low-grade chronic inflammation can contribute to myocardial dysfunction in SSc. Acute or subacute myocarditis may also occur and, when severe, can be associated with skeletal muscle myositis [<a href="#rid2">2,3,9,23</a>], representing a high-risk disease subset with an SSc and polymyositis overlap syndrome. (See  <a class="medical medical_review" href="/d/html/7550.html" rel="external">"Neuromuscular manifestations of systemic sclerosis (scleroderma)", section on 'Myopathy'</a>.)</p><p>Coronary microvascular dysfunction in SSc leads to focal ischemia and injury mediated via transforming growth factor beta 1, reactive oxygen species, and inflammatory mediators [<a href="#rid3">3</a>]. Inflammation of the myocardium results in fibrosis leading to diastolic and/or systolic dysfunction [<a href="#rid4">4</a>].</p><p>Myocardial inflammation significantly contributes to systolic dysfunction in SSc [<a href="#rid24">24</a>]. While endomyocardial biopsy frequently reveals focal replacement fibrosis, CMR studies have demonstrated diffuse subendocardial interstitial fibrosis following a noncoronary distribution [<a href="#rid25">25,26</a>], similar to patterns seen in other inflammatory and infiltrative cardiomyopathies [<a href="#rid27">27</a>]. Myocarditis may occur in patients with SSc with myositis [<a href="#rid9">9,23</a>] and is a significant risk factor for developing LV systolic dysfunction. In one study, patients with SSc with myocarditis had shorter disease duration, cytoplasmic antineutrophil cytoplasmic antibody (c-ANCA)/antiproteinase 3 (PR3) antibody positivity, and concomitant skeletal myositis [<a href="#rid24">24</a>].</p><p class="headingAnchor" id="H175855482"><span class="h1">SCREENING FOR CARDIAC INVOLVEMENT</span><span class="headingEndMark"> — </span>Given the high morbidity and mortality of cardiac involvement in systemic sclerosis (SSc), screening for cardiac involvement is essential for early detection. Unlike the guidelines for screening and detecting pulmonary arterial hypertension (PAH) in SSc [<a href="#rid28">28-30</a>], there are limited data to guide the screening recommendations for primary cardiac involvement.</p><p class="headingAnchor" id="H3748743813"><span class="h2">Our screening approach</span><span class="headingEndMark"> — </span>Given the high prevalence of subclinical cardiac disease in SSc, we suggest initial baseline cardiac screening in all patients with SSc. Our approach to initial baseline screening and ongoing annual screening for patients with SSc for cardiac involvement, which is generally consistent with guidelines developed by professional organizations, is as follows [<a href="#rid31">31,32</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Focused history and physical examination.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>12-lead electrocardiogram (ECG).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Transthoracic echocardiogram (including 2D, Doppler, and tissue Doppler imaging).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Laboratory testing, including determination of autoantibodies and measurement of natriuretic peptide levels (ie, plasma brain natriuretic peptide [BNP] or N-terminal of the prohormone BNP [NT-proBNP]) and cardiac troponin.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Additional cardiac testing, which includes ECG monitoring, stress testing, cardiac magnetic resonance (CMR), or cardiac catheterization, should typically be guided by symptoms or other evidence of cardiac involvement.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Referral to a cardiologist is appropriate if the initial or serial diagnostic evaluations are abnormal or patients have signs or symptoms concerning for cardiac involvement.</p><p></p><p>Patients with SSc who are at increased risk for cardiac involvement include those with diffuse cutaneous disease, male sex, and/or those with concerning signs such as a drop in diffusing capacity of the lungs for carbon monoxide (DLCO), dyspnea on exertion, or evidence of congestive heart failure. Note that although a reduction in DLCO is often attributable to primary lung disease, it can also be due to heart failure. Patients with any of these signs should have closer monitoring in conjunction with a cardiologist, with whom additional diagnostic testing can be discussed when appropriate.</p><p class="headingAnchor" id="H910424795"><span class="h2">History and physical examination</span><span class="headingEndMark"> — </span>A comprehensive cardiac-focused history should include questions related to heart failure, coronary artery disease, and arrhythmias. Similarly, a cardiac-focused physical examination should assess for findings suggestive of cardiovascular involvement in SSc.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Heart failure symptoms</strong> may include dyspnea at rest or with exertion, orthopnea, paroxysmal nocturnal dyspnea, decreased exercise tolerance, fatigue, and weight gain. Patients should be classified based on New York Heart Association classification  (<a class="graphic graphic_table graphicRef52683" href="/d/graphic/52683.html" rel="external">table 1</a>) [<a href="#rid2">2,33</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Heart failure signs</strong> typically include evidence of volume overload (pulmonary congestion with rales/crackles, leg edema, elevated jugular venous pressure, ascites, etc); variable cardiac murmurs (especially systolic murmurs from mitral and/or tricuspid regurgitation) may be heard.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Coronary artery disease (including coronary microvascular dysfunction) symptoms</strong> may include angina (substernal chest discomfort with or without dyspnea associated with exercise or other stressors) and/or decreased exercise tolerance.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Arrhythmia symptoms</strong> may include palpitations, presyncope, syncope, and, in some cases, symptoms of heart failure. Patients with an ongoing arrhythmia may have irregular pulse/heart sounds and be either tachycardic or bradycardic.</p><p></p><p class="headingAnchor" id="H3864836001"><span class="h2">Laboratory studies and testing</span><span class="headingEndMark"> — </span>Baseline and annual screening should include ECG, echocardiogram, and measurement of autoantibodies and circulating levels of natriuretic peptide (ie, plasma BNP or NT-proBNP) and cardiac troponin regardless of symptoms. Additional cardiac testing is typically guided by signs and symptoms or other evidence of cardiac involvement. SSc-specific antibodies obtained during the initial diagnostic workup for SSc may inform the need for closer cardiac monitoring depending on the specific autoantibody profile and other associated risks.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Electrocardiography</strong> – We perform an annual 12-lead ECG in patients with SSc, regardless of symptoms, to screen for conduction system abnormalities. Patients with palpitations or conduction abnormalities on 12-lead ECG require further evaluation, including Holter monitoring. (See  <a class="medical medical_review" href="/d/html/961.html" rel="external">"Arrhythmia management for the primary care clinician", section on 'Approach to the patient'</a> and  <a class="medical medical_review" href="/d/html/907.html" rel="external">"Etiology of atrioventricular block"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Echocardiography</strong> – Echocardiography (including 2D, Doppler, and tissue Doppler imaging) is the mainstay in the evaluation for cardiac involvement in SSc, providing crucial information on left ventricular (LV) and right ventricular (RV) size and systolic function, diastolic function, valvular disease, and pericardial disease as well as noninvasive estimates of hemodynamics. Our practice is to perform annual echocardiograms in all patients with SSc to evaluate for emerging cardiopulmonary complications, including pulmonary hypertension (PH) across classifications (eg, Group 1 versus Group 2 versus Group 3 PH). Echocardiography may also distinguish pre-capillary from post-capillary etiologies of PH in SSc. (See  <a class="medical medical_review" href="/d/html/4377.html" rel="external">"Overview of pulmonary complications of systemic sclerosis (scleroderma)", section on 'Echocardiography'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Brain natriuretic peptides</strong> – Compared with the general population, levels of BNP &gt;60 pg/mL or NT-proBNP &gt;125 pg/mL signify possible cardiovascular involvement in the patient with SSc [<a href="#rid31">31</a>]. Elevated BNP, however, should be taken in the clinical context and associated with other correlating signs and symptoms of congestive heart failure. Notably, a significant change (ie, increase) in BNP or NT-proBNP from baseline should be considered highly suspicious for underlying cardiac involvement or PAH. (See  <a class="medical medical_review" href="/d/html/3486.html" rel="external">"Natriuretic peptide measurement in heart failure"</a> and  <a class="medical medical_review" href="/d/html/17124.html" rel="external">"Natriuretic peptide measurement in non-heart failure settings"</a>.)</p><p></p><p class="bulletIndent1">While BNP and NT-proBNP have lower thresholds for clinical significance in SSc and are known to be disproportionately elevated in SSc-PAH [<a href="#rid34">34</a>], elevated levels of these biomarkers are nonspecific, also increasing in LV systolic dysfunction, LV diastolic dysfunction, and myocardial ischemia [<a href="#rid35">35,36</a>]. In one study, NT-proBNP levels were higher in patients with SSc over 3.5 years of follow-up when compared with age- and sex-matched healthy controls, regardless of other cardiac risk factors and/or the presence of PAH [<a href="#rid37">37</a>]. Long-term survival was worse in patients with an increase of both NT-proBNP and troponin, diffuse subtype, abnormal skin score, diminished LV systolic function, and right bundle branch block (RBBB) on ECG, a known independent predictor of mortality in SSc [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiac troponin</strong> – Cardiac troponin T (cTnT) is a sensitive and specific biomarker for cardiac injury; however, it may be nonspecific in patients with concomitant chronic kidney disease (CKD) where troponin clearance is reduced. When elevated in patients with SSc, primary myocardial damage, inflammation, and/or direct cardiac involvement should be suspected [<a href="#rid24">24,35,37,39,40</a>]. cTnT may be a useful clinical tool to detect subclinical cardiac involvement in SSc and, when seen in conjunction with elevated NT-proBNP, LV systolic dysfunction, RBBB by ECG, and in patients with diffuse cutaneous involvement, should prompt thorough evaluation for myocardial disease [<a href="#rid31">31,35,37,39</a>]. Troponin elevation is independently associated with mortality in SSc [<a href="#rid41">41</a>]. Overlap skeletal myositis and inflammatory myocarditis should also be considered with further assessment by CMR [<a href="#rid42">42</a>]. (See  <a class="medical medical_review" href="/d/html/86.html" rel="external">"Troponin testing: Clinical use"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SSc-specific antibodies</strong> – While there are no autoantibodies specific for cardiac involvement in SSc, some autoantibodies are associated with a higher risk for cardiopulmonary complications, and their identification may warrant closer monitoring for cardiac involvement. Autoantibodies in SSc are the strongest predictor of clinical outcomes [<a href="#rid7">7</a>]. Anticentromere antibodies, commonly seen in patients with the limited cutaneous form of SSc, are associated with an increased risk for PAH. Antibodies to topoisomerase I and RNA polymerase III may be related to an increased risk of myocardial involvement. Antibodies to PM-Scl may be associated with myocarditis and antibodies to U1-RNP may be associated with pericarditis. Importantly, autoantibody profiles in SSc remain stable over time, are mutually exclusive, do not vary with disease activity, unlike inflammatory biomarkers, and are associated with distinct clinical phenotypes. (See  <a class="medical medical_review" href="/d/html/7539.html" rel="external">"Clinical manifestations and diagnosis of systemic sclerosis (scleroderma) in adults", section on 'Laboratory testing'</a> and  <a class="medical medical_review" href="/d/html/4368.html" rel="external">"Clinical manifestations, evaluation, and diagnosis of interstitial lung disease in systemic sclerosis (scleroderma)", section on 'Laboratory findings'</a>.)</p><p></p><p class="headingAnchor" id="H1476101612"><span class="h1">CARDIAC MANIFESTATIONS</span><span class="headingEndMark"> — </span>The spectrum of clinical cardiac manifestations in systemic sclerosis (SSc), shown in the figure  (<a class="graphic graphic_figure graphicRef121514" href="/d/graphic/121514.html" rel="external">figure 1</a>), includes vascular disease, conduction disease/arrhythmia, pericardial disease, and myocardial disease. The optimal evaluation and management of cardiac involvement in patients with SSc requires an integrated multidisciplinary approach involving rheumatologists, pulmonologists, and cardiologists.</p><p class="headingAnchor" id="H532310756"><span class="h2">Microvascular coronary artery disease</span><span class="headingEndMark"> — </span>Vascular involvement in SSc predominately affects the small arteries and arterioles rather than major epicardial arteries [<a href="#rid4">4</a>]. The prevalence of coronary microvascular dysfunction in SSc is unknown and associated with Raynaud phenomenon activity [<a href="#rid43">43</a>]. Coronary arteriolar vasospasm and coronary microvascular dysfunction are likely more prevalent than previously recognized and may represent an early preclinical phase of myocardial involvement. Microvascular dysfunction underlies fibrosis commonly seen on autopsy studies of patients with SSc  (<a class="graphic graphic_figure graphicRef121514" href="/d/graphic/121514.html" rel="external">figure 1</a>) [<a href="#rid4">4,44</a>]. (See  <a class="medical medical_review" href="/d/html/1479.html" rel="external">"Microvascular angina: Angina pectoris with normal coronary arteries"</a>.)</p><p>By contrast, the frequency of large-vessel atherosclerotic coronary disease in SSc appears similar to that of the general population and related to traditional risk factors such as diabetes, hypertension, and hyperlipidemia [<a href="#rid11">11</a>]. (See  <a class="medical medical_review" href="/d/html/1506.html" rel="external">"Overview of established risk factors for cardiovascular disease"</a>.)</p><p class="headingAnchor" id="H1159112119"><span class="h3">Clinical manifestations</span><span class="headingEndMark"> — </span>Some patients with SSc experience anginal-type chest pain (ie, substernal chest discomfort triggered by exercise or another stressor such as exposure to cold) in the absence of macrovascular obstructive disease due to pathologic changes in small coronary arteries and arterioles. However, there is likely a preclinical asymptomatic phase of coronary microvascular dysfunction [<a href="#rid11">11,12,45</a>]. For example, a small observational study demonstrated that impaired coronary flow reserve was more common in asymptomatic patients with SSc than in healthy controls [<a href="#rid11">11</a>]. Another study utilizing radionuclide myocardial perfusion imaging showed that regardless of symptoms, 60 percent of patients with SSc with both limited and diffuse cutaneous subtypes showed reversible myocardial perfusion defects [<a href="#rid14">14</a>].</p><p>Anginal symptoms are associated with a higher incidence of fixed or reversible defects on radionuclide myocardial perfusion imaging [<a href="#rid46">46</a>]. (See <a class="local">'Diagnostic evaluation'</a> below.)</p><p class="headingAnchor" id="H3456270956"><span class="h3">Diagnostic evaluation</span><span class="headingEndMark"> — </span>Patients with symptoms suggestive of myocardial ischemia should be evaluated for coronary artery disease. In patients with high-pretest probability for coronary artery disease, a referral to cardiology is indicated and may result in symptom-limited stress testing, typically with cardiac imaging, as exercise is generally the preferred form of stress for patients who can exercise and achieve an adequate cardiac workload and heart rate. Pharmacologic stress testing is typically performed when a patient is unable to exercise. The choice of concurrent imaging (eg, radionuclide myocardial perfusion or echocardiographic imaging) will vary depending on local availability and expertise.</p><p>The evaluation of patients with chest pain of suspected cardiac etiology, as well as our approach to selecting the optimal diagnostic modality, are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/1472.html" rel="external">"Approach to the patient with suspected angina pectoris"</a> and  <a class="medical medical_review" href="/d/html/1534.html" rel="external">"Stress testing for the diagnosis of obstructive coronary heart disease"</a> and  <a class="medical medical_review" href="/d/html/1502.html" rel="external">"Selecting the optimal cardiac stress test"</a>.)</p><p class="headingAnchor" id="H989439957"><span class="h3">Treatment</span><span class="headingEndMark"> — </span>There are no SSc-specific therapies for the treatment of microvascular angina. Similar to the general population of patients with coronary artery disease, patients with SSc should be optimized for anti-anginal treatment, which may include calcium channel blockers, nitrates, statins, and <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>. (See  <a class="medical medical_review" href="/d/html/1483.html" rel="external">"Chronic coronary syndrome: Overview of care", section on 'Antianginal therapy'</a>.)</p><p>Although beta blockers are frequently used for microvascular angina, in patients with SSc, beta blockers potentially exacerbate Raynaud’s phenomenon due to unopposed alpha-receptor activity. <a class="drug drug_general" data-topicid="9208" href="/d/drug information/9208.html" rel="external">Carvedilol</a> (a nonselective beta blocker with alpha blockade and dihydropyridine calcium channel blocker properties) might be used in patients with SSc-associated cardiac involvement and is generally well tolerated, even in combination with long-acting dihydropyridines. Limitations with both medications are related to bradycardia, significant conduction abnormalities, and/or low blood pressure.</p><p>Long-acting dihydropyridine calcium channel blockers might be used as anti-anginal therapy in patients with SSc, partly because of their additional benefit for treating Raynaud phenomenon. There are limited data regarding the use of calcium channel blockers for managing microvascular angina in patients with SSc, and the rationale for their use is primarily based on clinical experience and extrapolation from experience for vasospastic angina and microvascular angina. A large cohort study with 601 unselected patients with SSc found that using vasodilator therapy or low-dose acetylsalicylic acid was associated with a lower incidence of cardiac events at follow-up [<a href="#rid47">47</a>]. (See  <a class="medical medical_review" href="/d/html/7540.html" rel="external">"Treatment of Raynaud phenomenon: Initial management", section on 'Calcium channel blocker'</a> and  <a class="medical medical_review" href="/d/html/1481.html" rel="external">"Vasospastic angina", section on 'Initial therapy'</a> and  <a class="medical medical_review" href="/d/html/1479.html" rel="external">"Microvascular angina: Angina pectoris with normal coronary arteries", section on 'Management'</a> and  <a class="medical medical_review" href="/d/html/1479.html" rel="external">"Microvascular angina: Angina pectoris with normal coronary arteries", section on 'Initial therapy for rest or mixed angina'</a>.)</p><p class="headingAnchor" id="H2949029142"><span class="h2">Conduction defects and tachyarrhythmias</span><span class="headingEndMark"> — </span>Estimates of conduction defects in SSc range from 4 to 51 percent depending on whether resting electrocardiogram (ECG) or 24-hour ambulatory ECG monitoring is used [<a href="#rid48">48</a>]. Conduction system disease, such as bundle branch blocks (BBB) and/or atrioventricular (AV) blocks, is likely due to fibrosis of the conduction system from recurrent microvascular ischemic insult and autonomic dysfunction [<a href="#rid39">39,48</a>].</p><p>Symptomatic supraventricular tachyarrhythmias tend to be more common than bradyarrhythmias [<a href="#rid2">2,3,48</a>]. Ventricular arrhythmias are less common but are associated with an increased risk of sudden death and mortality, especially when concurrent with skeletal myopathies and systolic dysfunction [<a href="#rid2">2,49</a>].</p><p class="headingAnchor" id="H2284142776"><span class="h3">Clinical manifestations</span><span class="headingEndMark"> — </span>The clinical presentation of patients with conduction defects or tachyarrhythmias can vary significantly depending upon the resulting bradycardia or tachycardia and the impact on hemodynamic status. However, most patients are generally asymptomatic or develop relatively mild symptoms.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Conduction defects</strong> – Ambulatory ECG monitoring (for 24 hours or longer) should be performed in symptomatic patients with a nondiagnostic 12-lead ECG, as this allows for longer-term assessment of average heart rates at rest and while active and will be more sensitive in detecting conduction defects and arrhythmia [<a href="#rid48">48,50,51</a>]. Patients with severe conduction system disease (eg, Mobitz type II second-degree AV block or third-degree [complete] AV block) are usually symptomatic with presyncope or syncope, exercise intolerance, and/or generalized fatigue. (See  <a class="medical medical_review" href="/d/html/910.html" rel="external">"Second-degree atrioventricular block: Mobitz type II"</a> and  <a class="medical medical_review" href="/d/html/911.html" rel="external">"Third-degree (complete) atrioventricular block"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tachyarrhythmias</strong> – Patients with tachyarrhythmias may present with palpitations or, more frequently, asymptomatic, presenting with nonspecific symptoms such as dyspnea on exertion, generalized fatigue, or exercise intolerance. On rare occasions, patients may present with sudden cardiac arrest due to sustained ventricular tachyarrhythmia.</p><p></p><p class="headingAnchor" id="H1562437004"><span class="h3">Diagnostic evaluation</span><span class="headingEndMark"> — </span>All patients with suspected conduction system disease or a tachyarrhythmia should have a resting 12-lead ECG. Additional evaluation will vary depending on the ECG findings and underlying symptoms (if any).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Conduction defects</strong> – Ambulatory ECG monitoring (for 24 hours or longer) should be performed in symptomatic patients with a nondiagnostic 12-lead ECG, as this allows for longer-term assessment of average heart rates at rest and while active and will be more sensitive in detecting conduction defects and arrhythmia [<a href="#rid31">31</a>]. In patients with exercise intolerance and resting bradycardia without evidence of conduction defects, an exercise stress test may help detect inappropriate heart rate response or chronotropic incompetence as the cause of symptoms.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tachyarrhythmias</strong> – Patients with palpitations suggesting a tachyarrhythmia should undergo ambulatory ECG monitoring for at least 24 hours. Extended ECG monitoring may be indicated when symptoms are less frequent and/or are associated with cardiogenic syncope. In cases with significant symptoms (eg, unexplained syncope) where noninvasive monitoring for up to 30 days is unrevealing, insertable cardiac monitors (ICMs; also sometimes referred to as implantable cardiac monitors or implantable loop recorders) may extend the ability to detect arrhythmias over a longer period. (See  <a class="medical medical_review" href="/d/html/958.html" rel="external">"Ambulatory ECG monitoring"</a>.)</p><p></p><p class="bulletIndent1">Given its potential pathogenic impact, further evaluation of coronary microvascular dysfunction is often warranted in patients with SSc with documented tachyarrhythmias. (See <a class="local">'Diagnostic evaluation'</a> above.)</p><p></p><p class="headingAnchor" id="H2478185812"><span class="h3">Treatment</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Conduction defects</strong> – If there is evidence of a significant conduction defect, medications that slow AV node conduction (eg, beta-blockers, nondihydropyridine calcium channel blockers, <a class="drug drug_general" data-topicid="9360" href="/d/drug information/9360.html" rel="external">digoxin</a>) should be avoided. Patients with evidence of high-grade AV block, symptomatic bradycardia, or symptomatic sinus node dysfunction (formerly called sick sinus syndrome) should be treated with a permanent pacemaker. Patients with early conduction system disease generally do not require treatment. (See  <a class="medical medical_review" href="/d/html/941.html" rel="external">"Permanent cardiac pacing: Overview of devices and indications"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tachyarrhythmias</strong> – There are limited data on the use of antiarrhythmic therapy, ablation therapy, or intracardiac devices such as pacemakers or defibrillators specifically in the SSc population [<a href="#rid48">48</a>]. Therapy should follow general treatment guidelines from professional societies and is discussed in detail separately [<a href="#rid52">52,53</a>]. (See  <a class="medical medical_review" href="/d/html/936.html" rel="external">"Overview of the acute management of tachyarrhythmias"</a>.)</p><p></p><p class="bulletIndent1">Beta-1 selective blockers should generally be avoided or used with caution given the possibility of exacerbating Raynaud phenomenon. <a class="drug drug_general" data-topicid="9208" href="/d/drug information/9208.html" rel="external">Carvedilol</a>, a nonselective beta blocker with additional blockades of alpha(1)-adrenoceptors, has less direct nodal effects and is not typically utilized for treating tachyarrhythmias. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="headingAnchor" id="H1209153196"><span class="h2">Autonomic insufficiency</span><span class="headingEndMark"> — </span>Autonomic insufficiency is frequent in SSc, occurs at early stages of the disease process, and might precede the development of myocardial fibrosis [<a href="#rid54">54</a>]. Lack of heart rate variability and resting tachycardia predict increased mortality in SSc [<a href="#rid48">48</a>].</p><p class="headingAnchor" id="H2546167337"><span class="h3">Clinical manifestation</span><span class="headingEndMark"> — </span>Patients with SSc and autonomic insufficiency present similarly to that of the general population, with symptoms of positional dizziness or orthostatic hypotension, inappropriate heart rate response to exertion or exercise intolerance, and inappropriate sweating or sensation of warmth. These symptoms may sometimes be associated with reflex (neurocardiogenic) syncope. (See  <a class="medical medical_review" href="/d/html/1050.html" rel="external">"Reflex syncope in adults and adolescents: Clinical presentation and diagnostic evaluation", section on 'Autonomic dysfunction'</a>.)</p><p class="headingAnchor" id="H3828996950"><span class="h3">Diagnostic evaluation</span><span class="headingEndMark"> — </span>If patients have clinical evidence of autonomic dysfunction, the first step is typically assessment of heart rate and blood pressure in supine, sitting, and standing positions. In some cases, tilt-table testing may be helpful to elucidate whether symptoms of inappropriate blood pressure and heart rate response are due to autonomic neuropathy. (See  <a class="medical medical_review" href="/d/html/1016.html" rel="external">"Upright tilt table testing in the evaluation of syncope"</a>.)</p><p class="headingAnchor" id="H1072706641"><span class="h3">Treatment</span><span class="headingEndMark"> — </span>Depending on the severity of symptoms, autonomic dysfunction is typically treated with conservative measures such as elevating the head of the bed, adequate hydration, liberation of salt intake, wearing compression stockings, and modification of changes in positioning. In some cases, medications such as <a class="drug drug_general" data-topicid="8455" href="/d/drug information/8455.html" rel="external">fludrocortisone</a> may be indicated. <a class="drug drug_general" data-topicid="9651" href="/d/drug information/9651.html" rel="external">Midodrine</a>, often used for autonomic and orthostatic dysfunction, is relatively contraindicated in SSc due to its vasoconstrictive effects, which can exacerbate Raynaud phenomenon. (See  <a class="medical medical_review" href="/d/html/5105.html" rel="external">"Treatment of orthostatic and postprandial hypotension"</a>.)</p><p>Treatment of a concomitant disease that may also contribute to autonomic dysfunction, such as diabetes, is also beneficial. Unfortunately, in many cases, no apparent underlying cause of autonomic dysfunction may be found.</p><p class="headingAnchor" id="H2972397304"><span class="h2">Pericardial involvement</span></p><p class="headingAnchor" id="H2792611304"><span class="h3">Clinical manifestations</span><span class="headingEndMark"> — </span>Pericardial involvement in SSc varies from 33 to 72 percent, most commonly asymptomatic pericardial effusions [<a href="#rid55">55</a>]. SSc-associated pericardial disease is symptomatic in 5 to 16 percent of patients and can be associated with considerable morbidity [<a href="#rid2">2,3,25,56</a>].</p><p>Pericardial involvement can present in the following ways:</p><p class="bulletIndent1"><span class="glyph">●</span>Pericardial effusion (asymptomatic or associated with cardiac tamponade)</p><p class="bulletIndent1"><span class="glyph">●</span>Acute pericarditis</p><p class="bulletIndent1"><span class="glyph">●</span>Constrictive pericarditis</p><p></p><p>Most patients with SSc and pericardial involvement are found to have an asymptomatic pericardial effusion. In such cases, the effusion has accumulated slowly and does not impact cardiac function. Patients who develop symptoms of increased intrapericardial pressure typically present with dyspnea, chest discomfort or fullness, peripheral edema, fatigue, or other symptoms related to increased filling pressures and limited cardiac output. Findings on physical examination (hypotension, tachycardia, dilated neck veins, and muffled heart sounds) are not highly sensitive or specific for the diagnosis. Pericardial effusions are typically small to moderate in size and rarely complicated by cardiac tamponade [<a href="#rid57">57</a>]. However, new-onset or worsening pericardial effusions should prompt evaluation for scleroderma renal involvement [<a href="#rid58">58</a>]. (See  <a class="medical medical_review" href="/d/html/4921.html" rel="external">"Cardiac tamponade"</a>.)</p><p>Less commonly, patients may manifest acute or chronic pericarditis, which has similar SSc presentation to the general population. Acute pericarditis is typically associated with pleuritic-type chest discomfort with or without a pericardial friction rub. Most patients with acute pericarditis do not have a significant pericardial effusion. Rarely, patients may present with evidence of constrictive pericarditis, a late occurrence following extended periods of pericardial inflammation [<a href="#rid57">57</a>]. Constrictive pericarditis may be challenging to diagnose in SSc until symptoms of right-sided heart failure such as abdominal distension, fatigue, dyspnea, and cardiac cachexia develop. (See  <a class="medical medical_review" href="/d/html/143126.html" rel="external">"Overview of pericardial disease"</a>.)</p><p class="headingAnchor" id="H2640143163"><span class="h3">Diagnostic evaluation</span><span class="headingEndMark"> — </span>The diagnostic approach for pericardial effusion, acute pericarditis, and constrictive pericarditis is the same as for patients without an underlying diagnosis of SSc. (See  <a class="medical medical_review" href="/d/html/4941.html" rel="external">"Pericardial effusion: Approach to diagnosis", section on 'Cardiac imaging'</a> and  <a class="medical medical_review" href="/d/html/4940.html" rel="external">"Acute pericarditis: Clinical presentation and diagnosis", section on 'Diagnostic evaluation'</a> and  <a class="medical medical_review" href="/d/html/4938.html" rel="external">"Constrictive pericarditis: Diagnostic evaluation", section on 'Initial tests'</a>.)</p><p>All patients with suspected pericardial involvement should have a 12-lead ECG and a transthoracic echocardiogram. Findings on ECG and echocardiography include:</p><p class="bulletIndent1"><span class="glyph">●</span>ECG findings – None (possible in pericardial effusion and constrictive pericarditis), diffuse ST elevation and PR depression (acute pericarditis), QRS alternans (in patients with large pericardial effusion). (See  <a class="medical medical_review" href="/d/html/4940.html" rel="external">"Acute pericarditis: Clinical presentation and diagnosis", section on 'Electrocardiogram'</a> and  <a class="medical medical_review" href="/d/html/4938.html" rel="external">"Constrictive pericarditis: Diagnostic evaluation", section on 'Electrocardiogram'</a> and  <a class="medical medical_review" href="/d/html/4941.html" rel="external">"Pericardial effusion: Approach to diagnosis", section on 'ECG findings'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Echocardiographic findings – Echocardiographic findings can be entirely normal but may also include pericardial effusion or other evidence of constrictive pericarditis (increased respiratory variation in mitral and tricuspid inflow, hepatic vein diastolic flow reversal during expiration, etc). (See  <a class="medical medical_review" href="/d/html/4940.html" rel="external">"Acute pericarditis: Clinical presentation and diagnosis", section on 'Echocardiogram'</a> and  <a class="medical medical_review" href="/d/html/4938.html" rel="external">"Constrictive pericarditis: Diagnostic evaluation", section on 'Echocardiography'</a> and  <a class="medical medical_review" href="/d/html/4941.html" rel="external">"Pericardial effusion: Approach to diagnosis", section on 'Echocardiography'</a>.)</p><p></p><p>Cardiac magnetic resonance (CMR) can also help assess pericardial disease in patients with SSc, especially when initial echocardiographic images are unclear or suboptimal or if localized pericardial disease may be suspected [<a href="#rid59">59</a>]. CMR allows for quantification of pericardial involvement and morphologic assessment, with high spatial resolution to demonstrate the involvement of adjacent structures. Further, due to excellent tissue characterization, CMR enables delineation of inflamed versus fibrotic tissue as well as functional imaging distinguishing between restrictive versus constrictive physiology (eg, dynamic increase in interventricular septal flattening at peak inspiration on deep breathing cine images is indicative of constrictive physiology). Respiratory flow variation of the mitral inflow velocities &gt;25 percent by CMR is sensitive and specific, similar to echocardiography, in identifying constrictive pericarditis [<a href="#rid59">59,60</a>].</p><p class="headingAnchor" id="H3808336984"><span class="h3">Treatment</span><span class="headingEndMark"> — </span>Pericardial involvement in patients with SSc is typically managed like other forms of pericarditis. Treatment varies according to the manifestation:</p><p class="bulletIndent1"><span class="glyph">●</span>Observation (asymptomatic small to moderate-size pericardial effusions).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pericardial fluid drainage (large or symptomatic effusions, or for diagnostic purposes). SSc-PAH can also be associated with pericardial effusion, and in those patients pericardiocentesis should only be used in the setting of cardiac tamponade given the possibility of cardiovascular compromise with drainage of the pericardial effusion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nonsteroidal antiinflammatory drugs (NSAIDs) and <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> (acute pericarditis).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pericardiectomy (rarely required for constrictive pericarditis).</p><p></p><p>Treatment of the specific entities is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/15800.html" rel="external">"Acute pericarditis: Treatment and prognosis"</a> and  <a class="medical medical_review" href="/d/html/4921.html" rel="external">"Cardiac tamponade"</a> and  <a class="medical medical_review" href="/d/html/140886.html" rel="external">"Constrictive pericarditis: Management and prognosis", section on 'Management of constrictive pericarditis'</a> and  <a class="medical medical_review" href="/d/html/143123.html" rel="external">"Pericardial effusion: Approach to management"</a>.)</p><p class="headingAnchor" id="H1547263876"><span class="h2">Heart failure</span><span class="headingEndMark"> — </span>Heart failure is a complex clinical syndrome that can result from any structural or functional cardiac disorder that impairs the ability of the ventricle to fill with or eject blood. It is characterized by dyspnea and fatigue, and signs of fluid retention. Many asymptomatic patients with diffuse cutaneous SSc who undergo CMR are found to have myocardial inflammation and/or diminished myocardial perfusion reserve index with evidence of diffuse fibrosis despite normal routine cardiac evaluation [<a href="#rid42">42</a>]. These findings suggest that early myocardial involvement in SSc can occur without cardiac symptoms. Clinically active myocarditis, while uncommon, is associated with significant morbidity and mortality and is typically associated with myositis and overlap syndromes. (See  <a class="medical medical_review" href="/d/html/7550.html" rel="external">"Neuromuscular manifestations of systemic sclerosis (scleroderma)", section on 'Myopathy'</a>.)</p><p class="headingAnchor" id="H3451421717"><span class="h3">Clinical manifestations</span><span class="headingEndMark"> — </span>Heart failure signs and symptoms may include dyspnea at rest or with exertion, orthopnea, paroxysmal nocturnal dyspnea, decreased exercise tolerance, fatigue, weight gain, and volume overload (pulmonary congestion with rales/crackles, leg edema, jugular venous distension, ascites, etc). Patients with symptomatic heart failure can be divided into two groups based upon their left ventricular (LV) ejection fraction: heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF). Right-sided heart failure and right ventricular (RV) dysfunction can result from HFpEF or HFrEF. Occasionally, patients with SSc may present with acute myocarditis and clinical decompensation, which should prompt urgent hospitalization and attempts to confirm the diagnosis using cardiac MRI or endomyocardial biopsy. (See <a class="local">'Diagnostic evaluation'</a> below and <a class="local">'Treatment'</a> below.)</p><p>Diastolic dysfunction is a key pathophysiologic factor underlying the clinical syndrome of HFpEF, the most common presentation of heart failure in patients with SSc. Diastolic dysfunction reflecting impaired ventricular filling represents a stiff ventricle, which may lead to upstream effects such as atrial enlargement, associated arrhythmias, and pulmonary venous congestion and edema.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Left ventricular diastolic dysfunction</strong> – LV dysfunction in SSc is thought to be due to focal ischemia from microvascular disease, leading to inflammation and myocardial fibrosis [<a href="#rid4">4</a>], and ultimately to a stiff LV. Reduced LV compliance may also be due to primary stiffening of cardiomyocytes due to abnormalities in titin phosphorylation, which can also be induced by coronary microvascular dysfunction and reduced nitric oxide bioavailability. Diastolic dysfunction may occur early in diffuse SSc independent of comorbid cardiac abnormalities such as essential hypertension [<a href="#rid20">20</a>]. Studies suggest that diastolic dysfunction is highly prevalent in SSc, with estimates ranging between 20 to 60 percent [<a href="#rid20">20,22,61</a>]. Diastolic dysfunction typically appears before clinical symptoms of heart failure, regardless of SSc disease subtype, and is associated with increased mortality [<a href="#rid21">21,61</a>]. Risk factors for diastolic dysfunction in SSc include older age, longer disease duration, diffuse cutaneous involvement, and presence of cardiovascular risk factors such as essential hypertension and ischemic heart disease [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent1">The clinical manifestations of HFpEF are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/3504.html" rel="external">"Heart failure with preserved ejection fraction: Clinical manifestations and diagnosis", section on 'Clinical manifestations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Left ventricular systolic dysfunction</strong> – LV systolic dysfunction is far less common in SSc than diastolic dysfunction, with an estimated incidence of 11 to 15 percent depending on diagnostic technique [<a href="#rid2">2</a>]. Overt LV systolic dysfunction is uncommon but, when present, is thought to be due to coronary artery disease [<a href="#rid62">62</a>]. LV systolic dysfunction may also result from myocarditis, a critical potential sequelae in patients with SSc and myositis [<a href="#rid9">9,23,63</a>]. Observational data suggest that patients with SSc with systolic dysfunction are more likely to be older males with digital ulcerations, concomitant myositis, and lung involvement who have not received medical treatment with calcium channel blockers [<a href="#rid20">20,22,64</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Right ventricular systolic dysfunction</strong> – RV dysfunction in SSc may result from HFpEF or HFrEF involving the LV, from primary abnormalities of the RV, or secondary to pulmonary arterial hypertension (PAH). Clinical manifestations of right-sided heart failure, such as peripheral volume overload (fatigue, dyspnea, dependent edema, ascites, jugular venous distension, etc) are described separately (see  <a class="medical medical_review" href="/d/html/113235.html" rel="external">"Clinical manifestations and diagnosis of advanced heart failure"</a>). Translational studies suggest that intrinsic cardiomyocyte abnormalities (depressed sarcomere function) [<a href="#rid65">65</a>] may predispose SSc patients to right heart failure and poor clinical outcomes [<a href="#rid66">66,67</a>] when compared with other subtypes of PAH.</p><p></p><p class="bulletIndent1">Despite routine clinical and echocardiographic monitoring, RV involvement and PAH prediction in SSc remain imprecise [<a href="#rid68">68</a>]. Although two-dimensional echocardiography is a useful screening tool in PAH [<a href="#rid29">29</a>], RV dysfunction is often undetected or underestimated [<a href="#rid69">69</a>]. Speckle-tracking echocardiography (STE) has several advantages and can be used with conventional two-dimensional echocardiography to optimize RV imaging [<a href="#rid70">70</a>]. STE-based studies have demonstrated that SSc patients have unique patterns of RV contractility [<a href="#rid71">71</a>] that precede the development of PH, and alone [<a href="#rid72">72</a>] and when coupled with exercise, may provide important insights into emerging PH and poor clinical outcomes [<a href="#rid73">73,74</a>]. Echocardiographic metrics can also detect clinical improvement in SSc [<a href="#rid75">75</a>] and improve with upfront therapies in PAH [<a href="#rid76">76</a>]. Newer echocardiographic variables that incorporate measures of RV function to pulmonary pressure [<a href="#rid77">77</a>] have been shown to predict incident PH in SSc [<a href="#rid78">78</a>] and may improve upon existing screening algorithms [<a href="#rid79">79</a>].</p><p></p><p class="headingAnchor" id="H1858529585"><span class="h3">Diagnostic evaluation</span><span class="headingEndMark"> — </span>The initial diagnostic evaluation in patients with SSc and suspected heart failure symptoms is the same as for those without SSc. The assessment typically includes laboratory testing for brain natriuretic peptide (BNP) levels and cardiac troponin T (cTnT), echocardiography, and, in select cases (eg, suspected myocarditis, nondiagnostic echocardiographic images) cardiac magnetic resonance (CMR). Serum cTnT and creatine kinase MB fraction (CK-MB) are not typically elevated in SSc-associated cardiomyopathy and, if elevated, should raise suspicion for myopericarditis, acute coronary syndrome, or pulmonary embolism [<a href="#rid2">2,80</a>]. Novel approaches to right heart and pulmonary vasculature imaging is an important area of active investigation in SSc and systemic inflammatory diseases [<a href="#rid81">81</a>]. Right heart catheterization (RHC) with or without endomyocardial biopsy may also be a part of the evaluation in selected patients. (See  <a class="medical medical_review" href="/d/html/3497.html" rel="external">"Approach to diagnosis and evaluation of acute decompensated heart failure in adults", section on 'Diagnostic evaluation'</a>.)</p><p>Echocardiography is at the forefront of screening and early detection of cardiac manifestations in SSc, including diastolic dysfunction, and emerging PH across subtypes. We perform yearly screening with echocardiography. In some cases, additional provocative testing may be helpful when there are borderline pulmonary pressures and/or signs of emerging right heart dysfunction from resting echocardiography [<a href="#rid73">73</a>]. Both resting and exercise stress echo may also reveal whether pulmonary pressures are elevated due to Group 1 PH versus primarily being driven by left heart disease (Group 2 PH) [<a href="#rid82">82</a>].</p><p>Currently, no evidence supports using CMR as a <strong>screening</strong> tool for detecting SSc cardiac involvement in asymptomatic patients. It is our clinical practice to refer patients with SSc for CMR in the following instances:</p><p class="bulletIndent1"><span class="glyph">●</span>If echocardiographic findings suggest global LV systolic dysfunction in the absence of ischemic etiologies</p><p class="bulletIndent1"><span class="glyph">●</span>If there is a concern for overlapping inflammatory processes</p><p class="bulletIndent1"><span class="glyph">●</span>If there is a persistent elevation in cardiac enzymes of unexplained etiology</p><p class="bulletIndent1"><span class="glyph">●</span>If myocarditis or constrictive pericarditis is suspected</p><p></p><p>CMR is the gold standard for evaluating cardiac structure and function due to excellent spatial resolution, especially when assessing the RV [<a href="#rid16">16-18,25,42,83,84</a>]. In addition, stress CMR can detect coronary microvascular dysfunction. In a cross-sectional study utilizing CMR, RV ejection fraction was reduced in patients with SSc compared with controls and was even lower in those with diffuse cutaneous SSc [<a href="#rid83">83</a>]. CMR is also beneficial for tissue characterization and can reliably detect myocardial inflammation versus fibrosis in addition to early perfusion defects [<a href="#rid42">42</a>]. The detection of fibrosis due to myocardial scar is based on the differential uptake of gadolinium in scarred fibrotic and adjacent non-fibrotic myocardial tissue [<a href="#rid42">42</a>]. Patients with late gadolinium enhancement (LGE), indicative of focal myocardial fibrosis, are at risk for arrhythmia and LV dysfunction [<a href="#rid42">42</a>]. Patients with SSc show a unique patchy mid-wall pattern of LGE of the basal and mid-LV segments that differs from regional subendocardial or transmural LGE pattern that typically characterizes prior myocardial infarction [<a href="#rid42">42</a>].</p><p>The definitive diagnosis of PH requires invasive cardiac hemodynamic assessment with RHC [<a href="#rid29">29</a>]. It is our clinical practice to refer patients with SSc for RHC if there is elevated pulmonary artery systolic pressure ≥35 mmHg on resting echocardiogram or moderate to severe right-sided chamber dilatation or RV dysfunction. Clinical judgment is based on symptoms and abnormal echocardiographic findings, pulmonary function testing, and laboratory data. A common diagnostic challenge is the distinction between PAH and PH due to left-sided heart disease. PH is defined as mean PAP &gt;20 mmHg at rest, assessed by RHC [<a href="#rid29">29</a>]. Endomyocardial biopsy performed during RHC may be indicated in SSc if infiltrative cardiac disease, drug toxicity [<a href="#rid85">85</a>], or overlap myocarditis [<a href="#rid86">86</a>] is suspected. Left heart catheterization includes coronary angiography, the gold standard for assessing and managing obstructive coronary artery disease, coronary flow reserve testing, and invasive measurements of LV end-diastolic pressure and/or transaortic gradients. Simultaneous LV and RV end-diastolic pressure measurements allow for the differentiation between constrictive and restrictive cardiomyopathies.</p><p class="headingAnchor" id="H282694550"><span class="h3">Treatment</span><span class="headingEndMark"> — </span>Generally, the management of cardiomyopathy associated with SSc is the same as for patients without SSc. The goals of therapy include:</p><p class="bulletIndent1"><span class="glyph">●</span>Management of symptoms</p><p class="bulletIndent1"><span class="glyph">●</span>Management of volume overload</p><p class="bulletIndent1"><span class="glyph">●</span>Control of underlying risk factors (eg, hypertension) or provoking factors (eg, myocardial ischemia)</p><p class="bulletIndent1"><span class="glyph">●</span>Optimization of long-term outcomes</p><p></p><p>Treatment varies depending on whether the patient has HFpEF or HFrEF. The approach to heart failure therapy is discussed in detail separately (see  <a class="medical medical_review" href="/d/html/3461.html" rel="external">"Treatment and prognosis of heart failure with preserved ejection fraction"</a> and  <a class="medical medical_review" href="/d/html/121085.html" rel="external">"Overview of the management of heart failure with reduced ejection fraction in adults"</a>). Guideline-directed treatment of HFpEF and HFrEF must be individualized to the SSc patient because trials of these medications have not been conducted specifically in SSc. Patients with HFpEF and HFrEF will most likely tolerate mineralocorticoid receptor antagonists and sodium-glucose co-transporter 2 (SGLT2) inhibitors. Patients with HFpEF should not be treated with beta blockers unless there are other indications for these drugs. Patients with HFrEF should be treated with a nonselective beta blocker such as <a class="drug drug_general" data-topicid="9208" href="/d/drug information/9208.html" rel="external">carvedilol</a>. The choice of angiotensin receptor-neprilysin inhibitors (ARNIs), angiotensin-converting enzyme (ACE) inhibitors, and angiotensin receptor blockers (ARBs) should be used in SSc according to their heart failure indications (eg, left ventricular ejection fraction &lt;55 to 60 percent for ARNIs) and other potential SSc-related indications (eg, ACE inhibitors for scleroderma renal crisis). </p><p>Acute myocarditis or myopericarditis may respond to the addition of immunosuppressive therapy. We suggest treatment with immunosuppressive therapy and the typical treatment of cardiomyopathy for biopsy-proven or high clinical suspicion for SSc-associated myocarditis. We usually use low-dose glucocorticoids (less than 10 to 20 mg daily of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> or equivalent) in combination with <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>. <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">Mycophenolate</a> may be a reasonable alternative to cyclophosphamide, given the coexistence of other disease manifestations for which mycophenolate is used. This approach to therapy is based mainly on clinical experience, observational data, and extrapolation from immunosuppressive trials for other manifestations of SSc. Since high doses of glucocorticoids are recognized as a risk factor for scleroderma renal crisis, we use only low-dose glucocorticoid therapy with close monitoring for new onset of hypertension. Cyclophosphamide is typically given for three to six months and then replaced by a medication with a lower risk of toxicity, such as <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> or mycophenolate [<a href="#rid24">24,31</a>]. (See  <a class="medical medical_review" href="/d/html/7963.html" rel="external">"General principles of the use of cyclophosphamide in rheumatic diseases"</a> and  <a class="medical medical_review" href="/d/html/7987.html" rel="external">"General toxicity of cyclophosphamide in rheumatic diseases"</a>.)</p><p>Limited observational data suggests that treatment with glucocorticoids and <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> results in clinical improvement and normalization of cardiac enzymes [<a href="#rid24">24,87</a>]. In a case series of six patients with diffuse cutaneous SSc and myocarditis, the two patients treated with glucocorticoids died due to progressive LV failure despite apparent clinical improvement [<a href="#rid23">23</a>]. Clinical improvement following the use of combination therapy including intravenous <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG) has been reported in myocarditis and, as such, IVIG might also be an appropriate add-on treatment option in some patients with SSc-associated myocarditis [<a href="#rid88">88</a>].</p><p class="headingAnchor" id="H1020050842"><span class="h2">Cardiotoxicity from systemic sclerosis therapies</span><span class="headingEndMark"> — </span>Unfortunately, some treatments used to treat SSc may have adverse cardiovascular side effects. These include <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> [<a href="#rid89">89</a>] and autologous stem cell transplantation [<a href="#rid90">90</a>]. Although stem cell transplantation likely does not cause cardiotoxicity, myeloablative doses of cyclophosphamide can. Patients with SSc and preexisting cardiac dysfunction are at increased risk for morbidity and mortality with stem cell transplantation [<a href="#rid91">91</a>]. High-dose cyclophosphamide therapy can be complicated by LV or RV systolic dysfunction, especially in those patients with SSc who are older or have abnormal cardiac function. Rarely, cyclophosphamide has resulted in early hemorrhagic myopericarditis [<a href="#rid92">92</a>], which may be associated with pericardial effusion and cardiac tamponade. Non-myeloablative doses of cyclophosphamide are uncommonly associated with cardiac toxicity (see  <a class="medical medical_review" href="/d/html/7987.html" rel="external">"General toxicity of cyclophosphamide in rheumatic diseases"</a>). Therefore, screening with echocardiography or CMR prior to stem cell transplantation is crucial to exclude cardiac dysfunction.</p><p class="headingAnchor" id="H2771568389"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Cardiac involvement in systemic sclerosis (SSc) is a harbinger of aggressive systemic disease [<a href="#rid1">1,3,93,94</a>]. A meta-analysis with 11,526 person-years of follow-up found that clinically overt cardiac involvement was associated with a 2.8-fold increased risk of death and was the strongest predictor of mortality [<a href="#rid93">93,94</a>]. In another study of 5860 patients with SSc, 26 percent of deaths were attributable to cardiac involvement. Cardiac involvement, the third leading cause of death following interstitial lung disease and pulmonary arterial hypertension (PAH), was primarily due to heart failure and arrhythmias [<a href="#rid1">1</a>]. Studies demonstrate that while mortality from SSc-associated PAH has improved, there has been minimal change in survival rates from SSc pulmonary hypertension (PH) resulting from Group 2 [<a href="#rid94">94,95</a>] and Group 3 disease [<a href="#rid96">96</a>]. </p><p>Clinically overt cardiac involvement is also a significant factor in SSc deaths due to other causes. For instance, in a retrospective review, 60 percent of SSc-related deaths over 30 years were attributable to PAH or pulmonary fibrosis [<a href="#rid93">93,94</a>]. PAH has the strongest correlation with increased mortality, affecting approximately 10 to 12 percent of patients with SSc, with a median survival of four years after diagnosis [<a href="#rid93">93,94</a>]. (See  <a class="medical medical_review" href="/d/html/8256.html" rel="external">"Pulmonary arterial hypertension in systemic sclerosis (scleroderma): Treatment and prognosis", section on 'Prognosis'</a>.)</p><p class="headingAnchor" id="H362108008"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/118282.html" rel="external">"Society guideline links: Systemic sclerosis (scleroderma)"</a>.)</p><p class="headingAnchor" id="H61300209"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> – Cardiac involvement is common in systemic sclerosis (SSc) but frequently remains unrecognized until late in the disease. SSc-associated cardiac disease is associated with marked increases in morbidity and mortality; therefore, screening with appropriate diagnostic tools is essential. (See <a class="local">'Introduction'</a> above and <a class="local">'Epidemiology, etiology and pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Etiology</strong> – The broad categories of cardiac manifestations of SSc include vascular disease; conduction disease/arrhythmia and conduction disease; pericardial disease, including pericardial effusion and constrictive pericarditis; and myocardial disease, including left heart failure with preserved or reduced ejection fraction, right heart failure, restrictive cardiomyopathy, and myocarditis. (See <a class="local">'Epidemiology, etiology and pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening</strong> – Given the high prevalence of subclinical cardiac disease in SSc, we suggest initial baseline and annual cardiac screening in all patients. The evaluation includes a focused history and physical examination, with electrocardiogram (ECG), echocardiogram, and measurement of natriuretic peptides (brain natriuretic peptide [BNP] or N-terminal of the prohormone BNP [NT-proBNP]) and cardiac troponin regardless of symptoms. Additional cardiac testing, including stress testing, cardiac magnetic resonance (CMR) imaging, or cardiac catheterization, should be guided by symptoms or other evidence of cardiac involvement. Prompt referral to a cardiologist is appropriate if baseline or follow-up diagnostic evaluations are abnormal or signs or symptoms concerning for cardiac involvement are noted. (See <a class="local">'Screening for cardiac involvement'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Microvascular coronary artery disease</strong> – Vascular involvement in the heart in SSc predominately affects the small arteries and arterioles rather than major epicardial arteries. Some patients with SSc may experience anginal-type chest pain (ie, substernal chest discomfort triggered by exercise or another stressor) without obstructive disease due to pathologic changes in small coronary arteries and arterioles. Patients with symptoms suggestive of myocardial ischemia should be evaluated for large-vessel coronary artery disease. (See <a class="local">'Microvascular coronary artery disease'</a> above and <a class="local">'Clinical manifestations'</a> above and <a class="local">'Diagnostic evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of angina</strong> – There are no SSc-specific therapies for the treatment of microvascular angina. Similar to the general population of patients with coronary artery disease, patients with SSc should be optimized on anti-anginal medications, including calcium channel blockers, nitrates, statins, and <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>. Long-acting dihydropyridine calcium channel blockers are among the preferred anti-anginal medications for patients with SSc partly because of their additional benefit for treating Raynaud phenomenon. Unlike other forms of coronary artery disease, beta blockers are typically avoided in SSc due to the possibility of exacerbating Raynaud phenomenon. (See <a class="local">'Microvascular coronary artery disease'</a> above and <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Conduction system defects</strong> – Conduction system defects and arrhythmias are likely due to fibrosis of the conduction system from recurrent microvascular ischemic insult and autonomic dysfunction. Symptomatic supraventricular tachyarrhythmias are more common than bradyarrhythmias. The evaluation and treatment of patients with SSc with conduction system defects and/or arrhythmias is generally the same as for patients without SSc. (See <a class="local">'Conduction defects and tachyarrhythmias'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Autonomic insufficiency</strong> – Autonomic insufficiency is frequently seen in SSc, occurs early in the disease, and can precede the development of myocardial fibrosis. Patients with SSc with autonomic insufficiency present similar to the general population, with symptoms of positional dizziness or orthostatic hypotension, inappropriate heart rate response to exertion or exercise intolerance, and inappropriate sweating or sensation of warmth. The evaluation and treatment of patients with SSc and autonomic dysfunction is generally the same as for patients without SSc. (See <a class="local">'Autonomic insufficiency'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pericardial disease</strong> – Pericardial involvement in patients with SSc can include pericardial effusions (asymptomatic or associated with cardiac tamponade), acute pericarditis, or constrictive pericarditis. The diagnostic approach and treatment of patients with SSc complicated by pericardial involvement is typically managed the same was as patients without SSc. (See <a class="local">'Pericardial involvement'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Heart failure</strong> – Cardiac manifestations of SSc include left ventricular (LV) diastolic and systolic dysfunction and right ventricular (RV) systolic dysfunction. LV diastolic dysfunction, the most common manifestation, typically precedes clinical heart failure. Overt LV systolic dysfunction is uncommon and may be due to coronary artery disease or, less commonly, myocarditis. RV systolic dysfunction in SSc may be the result of heart failure with preserved ejection fraction (HFpEF) or heart failure with reduced ejection fraction (HFrEF) involving the left ventricle, the development of primary abnormalities of the right ventricle, or secondary to pulmonary arterial hypertension (PAH). The evaluation and management of cardiomyopathy associated with SSc is the same as for patients without SSc. (See <a class="local">'Heart failure'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Myocarditis</strong> – For patients with biopsy-proven or high clinical suspicion for SSc-associated myocarditis, we suggest immunosuppressive therapy and the typical treatment of cardiomyopathy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). We usually give low-dose glucocorticoids (less than 10 to 20 mg daily of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> or equivalent) in combination with <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>. <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">Mycophenolate</a> may be a reasonable alternative to cyclophosphamide given the coexistence of other disease manifestations for which mycophenolate is used. This approach is largely based on clinical experience, limited observational data, and extrapolation of trials of immunosuppressive agents used for other manifestations of SSc. Since high doses of glucocorticoids are a known risk factor for scleroderma renal crisis, we use only low-dose glucocorticoids with close monitoring for new onset of hypertension. When cyclophosphamide is used, it is typically given for three to six months and then replaced by a medication with a lower risk of toxicity. (See <a class="local">'Heart failure'</a> above and <a class="local">'Treatment'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69:1809.</a></li><li><a class="nounderline abstract_t">Rangarajan V, Matiasz R, Freed BH. Cardiac complications of systemic sclerosis and management: recent progress. Curr Opin Rheumatol 2017; 29:574.</a></li><li><a class="nounderline abstract_t">Hung G, Mercurio V, Hsu S, et al. Progress in Understanding, Diagnosing, and Managing Cardiac Complications of Systemic Sclerosis. Curr Rheumatol Rep 2019; 21:68.</a></li><li><a class="nounderline abstract_t">Dumitru RB, Bissell LA, Erhayiem B, et al. Predictors of subclinical systemic sclerosis primary heart involvement characterised by microvasculopathy and myocardial fibrosis. Rheumatology (Oxford) 2021; 60:2934.</a></li><li><a class="nounderline abstract_t">Steen VD, Powell DL, Medsger TA Jr. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 1988; 31:196.</a></li><li><a class="nounderline abstract_t">Perera A, Fertig N, Lucas M, et al. Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody. Arthritis Rheum 2007; 56:2740.</a></li><li><a class="nounderline abstract_t">Nihtyanova SI, Denton CP. Autoantibodies as predictive tools in systemic sclerosis. Nat Rev Rheumatol 2010; 6:112.</a></li><li><a class="nounderline abstract_t">Santos CS, Morales CM, Castro CÁ, Álvarez ED. Clinical phenotype in scleroderma patients based on autoantibodies. Rheumatol Adv Pract 2023; 7:i26.</a></li><li><a class="nounderline abstract_t">Connolly CM, Paik JJ. Myopathy in systemic sclerosis. Curr Opin Rheumatol 2023; 35:341.</a></li><li><a class="nounderline abstract_t">Bulkley BH, Ridolfi RL, Salyer WR, Hutchins GM. Myocardial lesions of progressive systemic sclerosis. A cause of cardiac dysfunction. Circulation 1976; 53:483.</a></li><li><a class="nounderline abstract_t">Faccini A, Agricola E, Oppizzi M, et al. Coronary microvascular dysfunction in asymptomatic patients affected by systemic sclerosis - limited vs. diffuse form. Circ J 2015; 79:825.</a></li><li><a class="nounderline abstract_t">Alexander EL, Firestein GS, Weiss JL, et al. Reversible cold-induced abnormalities in myocardial perfusion and function in systemic sclerosis. Ann Intern Med 1986; 105:661.</a></li><li><a class="nounderline abstract_t">Kahan A, Devaux JY, Amor B, et al. Nifedipine and thallium-201 myocardial perfusion in progressive systemic sclerosis. N Engl J Med 1986; 314:1397.</a></li><li><a class="nounderline abstract_t">Mavrogeni S, Koutsogeorgopoulou L, Karabela G, et al. Silent myocarditis in systemic sclerosis detected by cardiovascular magnetic resonance using Lake Louise criteria. BMC Cardiovasc Disord 2017; 17:187.</a></li><li><a class="nounderline abstract_t">Vignaux O, Allanore Y, Meune C, et al. Evaluation of the effect of nifedipine upon myocardial perfusion and contractility using cardiac magnetic resonance imaging and tissue Doppler echocardiography in systemic sclerosis. Ann Rheum Dis 2005; 64:1268.</a></li><li><a class="nounderline abstract_t">Galea N, Rosato E, Gigante A, et al. Early myocardial damage and microvascular dysfunction in asymptomatic patients with systemic sclerosis: A cardiovascular magnetic resonance study with cold pressor test. PLoS One 2020; 15:e0244282.</a></li><li><a class="nounderline abstract_t">Iida H, Hanaoka H, Okada Y, et al. A low perfusion-metabolic mismatch in 99m Tl and 123 I-BMIPP scintigraphy predicts poor prognosis in systemic sclerosis patients with asymptomatic cardiac involvement. Int J Rheum Dis 2019; 22:1008.</a></li><li><a class="nounderline abstract_t">Giacomelli R, Di Cesare E, Cipriani P, et al. Pharmacological stress, rest perfusion and delayed enhancement cardiac magnetic resonance identifies very early cardiac involvement in systemic sclerosis patients of recent onset. Int J Rheum Dis 2017; 20:1247.</a></li><li><a class="nounderline abstract_t">Duboc D, Kahan A, Maziere B, et al. The effect of nifedipine on myocardial perfusion and metabolism in systemic sclerosis. A positron emission tomographic study. Arthritis Rheum 1991; 34:198.</a></li><li><a class="nounderline abstract_t">Hinchcliff M, Desai CS, Varga J, Shah SJ. Prevalence, prognosis, and factors associated with left ventricular diastolic dysfunction in systemic sclerosis. Clin Exp Rheumatol 2012; 30:S30.</a></li><li><a class="nounderline abstract_t">Tennøe AH, Murbræch K, Andreassen JC, et al. Left Ventricular Diastolic Dysfunction Predicts Mortality in Patients With Systemic Sclerosis. J Am Coll Cardiol 2018; 72:1804.</a></li><li><a class="nounderline abstract_t">Hinze AM, Perin J, Woods A, et al. Diastolic Dysfunction in Systemic Sclerosis: Risk Factors and Impact on Mortality. Arthritis Rheumatol 2022; 74:849.</a></li><li><a class="nounderline abstract_t">Azzam M, Awad A, Abugharbyeh A, Kahaleh B. Myocarditis in connective tissue diseases: an often-overlooked clinical manifestation. Rheumatol Int 2023; 43:1983.</a></li><li><a class="nounderline abstract_t">Pieroni M, De Santis M, Zizzo G, et al. Recognizing and treating myocarditis in recent-onset systemic sclerosis heart disease: potential utility of immunosuppressive therapy in cardiac damage progression. Semin Arthritis Rheum 2014; 43:526.</a></li><li><a class="nounderline abstract_t">Hachulla AL, Launay D, Gaxotte V, et al. Cardiac magnetic resonance imaging in systemic sclerosis: a cross-sectional observational study of 52 patients. Ann Rheum Dis 2009; 68:1878.</a></li><li><a class="nounderline abstract_t">Fernandes F, Ramires FJ, Arteaga E, et al. Cardiac remodeling in patients with systemic sclerosis with no signs or symptoms of heart failure: an endomyocardial biopsy study. J Card Fail 2003; 9:311.</a></li><li><a class="nounderline abstract_t">Mahrholdt H, Wagner A, Judd RM, et al. Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies. Eur Heart J 2005; 26:1461.</a></li><li><a class="nounderline abstract_t">Coghlan JG, Denton CP, Grünig E, et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis 2014; 73:1340.</a></li><li><a class="nounderline abstract_t">Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2023; 61.</a></li><li><a class="nounderline abstract_t">Brown Z, Proudman S, Morrisroe K, et al. Screening for the early detection of pulmonary arterial hypertension in patients with systemic sclerosis: A systematic review and meta-analysis of long-term outcomes. Semin Arthritis Rheum 2021; 51:495.</a></li><li><a class="nounderline abstract_t">Bissell LA, Anderson M, Burgess M, et al. Consensus best practice pathway of the UK Systemic Sclerosis Study group: management of cardiac disease in systemic sclerosis. Rheumatology (Oxford) 2017; 56:912.</a></li><li><a class="nounderline abstract_t">Avouac J, Fransen J, Walker UA, et al. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Ann Rheum Dis 2011; 70:476.</a></li><li><a class="nounderline abstract_t">Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2022; 79:1757.</a></li><li><a class="nounderline abstract_t">Mathai SC, Bueso M, Hummers LK, et al. Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension. Eur Respir J 2010; 35:95.</a></li><li><a class="nounderline abstract_t">Avouac J, Meune C, Chenevier-Gobeaux C, et al. Cardiac biomarkers in systemic sclerosis: contribution of high-sensitivity cardiac troponin in addition to N-terminal pro-brain natriuretic peptide. Arthritis Care Res (Hoboken) 2015; 67:1022.</a></li><li><a class="nounderline abstract_t">Gokcen N. Serum markers in systemic sclerosis with cardiac involvement. Clin Rheumatol 2023; 42:2577.</a></li><li><a class="nounderline abstract_t">Bosello S, De Luca G, Berardi G, et al. Cardiac troponin T and NT-proBNP as diagnostic and prognostic biomarkers of primary cardiac involvement and disease severity in systemic sclerosis: A prospective study. Eur J Intern Med 2019; 60:46.</a></li><li><a class="nounderline abstract_t">Draeger HT, Assassi S, Sharif R, et al. Right bundle branch block: a predictor of mortality in early systemic sclerosis. PLoS One 2013; 8:e78808.</a></li><li><a class="nounderline abstract_t">Bissell LA, Md Yusof MY, Buch MH. Primary myocardial disease in scleroderma-a comprehensive review of the literature to inform the UK Systemic Sclerosis Study Group cardiac working group. Rheumatology (Oxford) 2017; 56:882.</a></li><li><a class="nounderline abstract_t">Hughes M, Lilleker JB, Herrick AL, Chinoy H. Cardiac troponin testing in idiopathic inflammatory myopathies and systemic sclerosis-spectrum disorders: biomarkers to distinguish between primary cardiac involvement and low-grade skeletal muscle disease activity. Ann Rheum Dis 2015; 74:795.</a></li><li><a class="nounderline abstract_t">Paik JJ, Choi DY, Mukherjee M, et al. Troponin elevation independently associates with mortality in systemic sclerosis. Clin Exp Rheumatol 2022; 40:1933.</a></li><li><a class="nounderline abstract_t">Mavrogeni S, Pepe A, Nijveldt R, et al. Cardiovascular magnetic resonance in autoimmune rheumatic diseases: a clinical consensus document by the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2022; 23:e308.</a></li><li><a class="nounderline abstract_t">Wigley FM, Flavahan NA. Raynaud's Phenomenon. N Engl J Med 2016; 375:556.</a></li><li><a class="nounderline abstract_t">Markousis-Mavrogenis G, Bournia VK, Sfikakis PP, Mavrogeni SI. Raynaud phenomenon and microvasculopathy in systemic sclerosis: multi-modality imaging for diagnosis and evaluation. Curr Opin Rheumatol 2023; 35:324.</a></li><li><a class="nounderline abstract_t">Hsu HB, Kao CH. Usefulness of technetium-99m tetrofosmin SPECT to detect abnormal myocardial perfusion in systemic lupus erythematosus or systemic sclerosis patients. Clin Rheumatol 2003; 22:495.</a></li><li><a class="nounderline abstract_t">Ishida R, Murata Y, Sawada Y, et al. Thallium-201 myocardial SPET in patients with collagen disease. Nucl Med Commun 2000; 21:729.</a></li><li><a class="nounderline abstract_t">Valentini G, Huscher D, Riccardi A, et al. Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort study. Ann Rheum Dis 2019; 78:1576.</a></li><li><a class="nounderline abstract_t">Fairley JL, Ross L, Quinlivan A, et al. Sudden cardiac death, arrhythmias and abnormal electrocardiography in systemic sclerosis: A systematic review and meta-analysis. Semin Arthritis Rheum 2023; 62:152229.</a></li><li><a class="nounderline abstract_t">Follansbee WP, Zerbe TR, Medsger TA Jr. Cardiac and skeletal muscle disease in systemic sclerosis (scleroderma): a high risk association. Am Heart J 1993; 125:194.</a></li><li><a class="nounderline abstract_t">Ridolfi RL, Bulkley BH, Hutchins GM. The cardiac conduction system in progressive systemic sclerosis. Clinical and pathologic features of 35 patients. Am J Med 1976; 61:361.</a></li><li><a class="nounderline abstract_t">D'Angelo WA, Fries JF, Masi AT, Shulman LE. Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med 1969; 46:428.</a></li><li><a class="nounderline abstract_t">Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114:e385.</a></li><li><a class="nounderline abstract_t">Blomström-Lundqvist C, Scheinman MM, Aliot EM, et al. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias). Circulation 2003; 108:1871.</a></li><li><a class="nounderline abstract_t">Masini F, Galiero R, Pafundi PC, et al. Autonomic nervous system dysfunction correlates with microvascular damage in systemic sclerosis patients. J Scleroderma Relat Disord 2021; 6:256.</a></li><li class="breakAll">Scleroderma: From Pathogenesis to Comprehensive Management, Varga J, Denton CP, Wigley FP, et al (Eds), Springer, Boston 2012.</li><li><a class="nounderline abstract_t">Byers RJ, Marshall DA, Freemont AJ. Pericardial involvement in systemic sclerosis. Ann Rheum Dis 1997; 56:393.</a></li><li><a class="nounderline abstract_t">Hosoya H, Derk CT. Clinically Symptomatic Pericardial Effusions in Hospitalized Systemic Sclerosis Patients: Demographics and Management. Biomed Res Int 2018; 2018:6812082.</a></li><li><a class="nounderline abstract_t">McWhorter JE 4th, LeRoy EC. Pericardial disease in scleroderma (systemic sclerosis). Am J Med 1974; 57:566.</a></li><li><a class="nounderline abstract_t">Cosyns B, Plein S, Nihoyanopoulos P, et al. European Association of Cardiovascular Imaging (EACVI) position paper: Multimodality imaging in pericardial disease. Eur Heart J Cardiovasc Imaging 2015; 16:12.</a></li><li><a class="nounderline abstract_t">Thavendiranathan P, Verhaert D, Walls MC, et al. Simultaneous right and left heart real-time, free-breathing CMR flow quantification identifies constrictive physiology. JACC Cardiovasc Imaging 2012; 5:15.</a></li><li><a class="nounderline abstract_t">Qiao W, Bi W, Wang X, et al. Cardiac involvement assessment in systemic sclerosis using speckle tracking echocardiography: a systematic review and meta-analysis. BMJ Open 2023; 13:e063364.</a></li><li><a class="nounderline abstract_t">Mok MY, Lau CS, Chiu SS, et al. Systemic sclerosis is an independent risk factor for increased coronary artery calcium deposition. Arthritis Rheum 2011; 63:1387.</a></li><li><a class="nounderline abstract_t">Schurle DR, Evans RW, Cohlmia JB, Lin J. Restrictive cardiomyopathy in scleroderma. J Kans Med Soc 1984; 85:49.</a></li><li><a class="nounderline abstract_t">Allanore Y, Meune C, Vonk MC, et al. Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis. Ann Rheum Dis 2010; 69:218.</a></li><li><a class="nounderline abstract_t">Hsu S, Kokkonen-Simon KM, Kirk JA, et al. Right Ventricular Myofilament Functional Differences in Humans With Systemic Sclerosis-Associated Versus Idiopathic Pulmonary Arterial Hypertension. Circulation 2018; 137:2360.</a></li><li><a class="nounderline abstract_t">Hsu S, Houston BA, Tampakakis E, et al. Right Ventricular Functional Reserve in Pulmonary Arterial Hypertension. Circulation 2016; 133:2413.</a></li><li><a class="nounderline abstract_t">Tedford RJ, Mudd JO, Girgis RE, et al. Right ventricular dysfunction in systemic sclerosis-associated pulmonary arterial hypertension. Circ Heart Fail 2013; 6:953.</a></li><li><a class="nounderline abstract_t">Reynertson SI, Kundur R, Mullen GM, et al. Asymmetry of right ventricular enlargement in response to tricuspid regurgitation. Circulation 1999; 100:465.</a></li><li><a class="nounderline abstract_t">Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr 2010; 23:685.</a></li><li><a class="nounderline abstract_t">Geyer H, Caracciolo G, Abe H, et al. Assessment of myocardial mechanics using speckle tracking echocardiography: fundamentals and clinical applications. J Am Soc Echocardiogr 2010; 23:351.</a></li><li><a class="nounderline abstract_t">Mukherjee M, Chung SE, Ton VK, et al. Unique Abnormalities in Right Ventricular Longitudinal Strain in Systemic Sclerosis Patients. Circ Cardiovasc Imaging 2016; 9.</a></li><li><a class="nounderline abstract_t">Mukherjee M, Mercurio V, Tedford RJ, et al. Right ventricular longitudinal strain is diminished in systemic sclerosis compared with idiopathic pulmonary arterial hypertension. Eur Respir J 2017; 50.</a></li><li><a class="nounderline abstract_t">Mukherjee M, Mercurio V, Hsu S, et al. Assessment of right ventricular reserve utilizing exercise provocation in systemic sclerosis. Int J Cardiovasc Imaging 2021; 37:2137.</a></li><li><a class="nounderline abstract_t">Lu J, Jani V, Mercurio V, et al. Stress Echocardiographic Prediction of Emerging Pulmonary Vascular Disease in Systemic Sclerosis. J Am Soc Echocardiogr 2023; 36:259.</a></li><li><a class="nounderline abstract_t">Mukherjee M, Mercurio V, Balasubramanian A, et al. Defining minimal detectable difference in echocardiographic measures of right ventricular function in systemic sclerosis. Arthritis Res Ther 2022; 24:146.</a></li><li><a class="nounderline abstract_t">Hassoun PM, Zamanian RT, Damico R, et al. Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension. Am J Respir Crit Care Med 2015; 192:1102.</a></li><li><a class="nounderline abstract_t">Tello K, Wan J, Dalmer A, et al. Validation of the Tricuspid Annular Plane Systolic Excursion/Systolic Pulmonary Artery Pressure Ratio for the Assessment of Right Ventricular-Arterial Coupling in Severe Pulmonary Hypertension. Circ Cardiovasc Imaging 2019; 12:e009047.</a></li><li><a class="nounderline abstract_t">Colalillo A, Hoffmann-Vold AM, Pellicano C, et al. The role of TAPSE/sPAP ratio in predicting pulmonary hypertension and mortality in the systemic sclerosis EUSTAR cohort. Autoimmun Rev 2023; 22:103290.</a></li><li><a class="nounderline abstract_t">Colalillo A, Grimaldi MC, Vaiarello V, et al. In systemic sclerosis, the TAPSE/sPAP ratio can be used in addition to the DETECT algorithm for pulmonary arterial hypertension diagnosis. Rheumatology (Oxford) 2022; 61:2450.</a></li><li><a class="nounderline abstract_t">Weber BN, Garshick M, Abbate A, et al. Acute cardiovascular complications of immune-mediated systemic inflammatory diseases. Eur Heart J Acute Cardiovasc Care 2023; 12:792.</a></li><li><a class="nounderline abstract_t">Alenezi F, Covington TA, Mukherjee M, et al. Novel Approaches to Imaging the Pulmonary Vasculature and Right Heart. Circ Res 2022; 130:1445.</a></li><li><a class="nounderline abstract_t">D'Alto M, Romeo E, Argiento P, et al. Echocardiographic prediction of pre- versus postcapillary pulmonary hypertension. J Am Soc Echocardiogr 2015; 28:108.</a></li><li><a class="nounderline abstract_t">Bezante GP, Rollando D, Sessarego M, et al. Cardiac magnetic resonance imaging detects subclinical right ventricular impairment in systemic sclerosis. J Rheumatol 2007; 34:2431.</a></li><li><a class="nounderline abstract_t">Allanore Y, Meune C, Kahan A. Systemic sclerosis and cardiac dysfunction: evolving concepts and diagnostic methodologies. Curr Opin Rheumatol 2008; 20:697.</a></li><li><a class="nounderline abstract_t">Soong TR, Barouch LA, Champion HC, et al. New clinical and ultrastructural findings in hydroxychloroquine-induced cardiomyopathy--a report of 2 cases. Hum Pathol 2007; 38:1858.</a></li><li><a class="nounderline abstract_t">Cooper LT, Baughman KL, Feldman AM, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Circulation 2007; 116:2216.</a></li><li><a class="nounderline abstract_t">Stack J, McLaughlin P, Sinnot C, et al. Successful control of scleroderma myocarditis using a combination of cyclophosphamide and methylprednisolone. Scand J Rheumatol 2010; 39:349.</a></li><li><a class="nounderline abstract_t">Winter MP, Sulzgruber P, Koller L, et al. Immunomodulatory treatment for lymphocytic myocarditis-a systematic review and meta-analysis. Heart Fail Rev 2018; 23:573.</a></li><li><a class="nounderline abstract_t">Fraiser LH, Kanekal S, Kehrer JP. Cyclophosphamide toxicity. Characterising and avoiding the problem. Drugs 1991; 42:781.</a></li><li><a class="nounderline abstract_t">Bruera S, Sidanmat H, Molony DA, et al. Stem cell transplantation for systemic sclerosis. Cochrane Database Syst Rev 2022; 7:CD011819.</a></li><li><a class="nounderline abstract_t">Fujimaki K, Maruta A, Yoshida M, et al. Severe cardiac toxicity in hematological stem cell transplantation: predictive value of reduced left ventricular ejection fraction. Bone Marrow Transplant 2001; 27:307.</a></li><li><a class="nounderline abstract_t">Yamamoto R, Kanda Y, Matsuyama T, et al. Myopericarditis caused by cyclophosphamide used to mobilize peripheral blood stem cells in a myeloma patient with renal failure. Bone Marrow Transplant 2000; 26:685.</a></li><li><a class="nounderline abstract_t">Kolstad KD, Li S, Steen V, et al. Long-Term Outcomes in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry (PHAROS). Chest 2018; 154:862.</a></li><li><a class="nounderline abstract_t">Elhai M, Meune C, Avouac J, et al. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) 2012; 51:1017.</a></li><li><a class="nounderline abstract_t">Hassan HJ, Naranjo M, Ayoub N, et al. Improved Survival for Patients with Systemic Sclerosis-associated Pulmonary Arterial Hypertension: The Johns Hopkins Registry. Am J Respir Crit Care Med 2023; 207:312.</a></li><li><a class="nounderline abstract_t">Perelas A, Silver RM, Arrossi AV, Highland KB. Systemic sclerosis-associated interstitial lung disease. Lancet Respir Med 2020; 8:304.</a></li></ol></div><div id="topicVersionRevision">Topic 120198 Version 13.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20551155" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28957839" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Cardiac complications of systemic sclerosis and management: recent progress.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31813082" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Progress in Understanding, Diagnosing, and Managing Cardiac Complications of Systemic Sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34080001" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Predictors of subclinical systemic sclerosis primary heart involvement characterised by microvasculopathy and myocardial fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3348823" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17665460" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20125179" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Autoantibodies as predictive tools in systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36968636" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Clinical phenotype in scleroderma patients based on autoantibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37650694" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Myopathy in systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1248080" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Myocardial lesions of progressive systemic sclerosis. A cause of cardiac dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25740209" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Coronary microvascular dysfunction in asymptomatic patients affected by systemic sclerosis - limited vs. diffuse form.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3767147" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Reversible cold-induced abnormalities in myocardial perfusion and function in systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3486363" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Nifedipine and thallium-201 myocardial perfusion in progressive systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28716007" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Silent myocarditis in systemic sclerosis detected by cardiovascular magnetic resonance using Lake Louise criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15708883" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Evaluation of the effect of nifedipine upon myocardial perfusion and contractility using cardiac magnetic resonance imaging and tissue Doppler echocardiography in systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33351821" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Early myocardial damage and microvascular dysfunction in asymptomatic patients with systemic sclerosis: A cardiovascular magnetic resonance study with cold pressor test.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30729690" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A low perfusion-metabolic mismatch in 99m Tl and 123 I-BMIPP scintigraphy predicts poor prognosis in systemic sclerosis patients with asymptomatic cardiac involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28580766" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Pharmacological stress, rest perfusion and delayed enhancement cardiac magnetic resonance identifies very early cardiac involvement in systemic sclerosis patients of recent onset.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1994918" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The effect of nifedipine on myocardial perfusion and metabolism in systemic sclerosis. A positron emission tomographic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22338601" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Prevalence, prognosis, and factors associated with left ventricular diastolic dysfunction in systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30286924" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Left Ventricular Diastolic Dysfunction Predicts Mortality in Patients With Systemic Sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34927390" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Diastolic Dysfunction in Systemic Sclerosis: Risk Factors and Impact on Mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37587233" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Myocarditis in connective tissue diseases: an often-overlooked clinical manifestation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23932313" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Recognizing and treating myocarditis in recent-onset systemic sclerosis heart disease: potential utility of immunosuppressive therapy in cardiac damage progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19054830" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Cardiac magnetic resonance imaging in systemic sclerosis: a cross-sectional observational study of 52 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13680552" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Cardiac remodeling in patients with systemic sclerosis with no signs or symptoms of heart failure: an endomyocardial biopsy study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15831557" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23687283" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36028254" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33857705" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Screening for the early detection of pulmonary arterial hypertension in patients with systemic sclerosis: A systematic review and meta-analysis of long-term outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28160468" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Consensus best practice pathway of the UK Systemic Sclerosis Study group: management of cardiac disease in systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21081523" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35379504" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19643943" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25604469" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Cardiac biomarkers in systemic sclerosis: contribution of high-sensitivity cardiac troponin in addition to N-terminal pro-brain natriuretic peptide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37335406" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Serum markers in systemic sclerosis with cardiac involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30366614" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Cardiac troponin T and NT-proBNP as diagnostic and prognostic biomarkers of primary cardiac involvement and disease severity in systemic sclerosis: A prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24205321" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Right bundle branch block: a predictor of mortality in early systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27940590" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Primary myocardial disease in scleroderma-a comprehensive review of the literature to inform the UK Systemic Sclerosis Study Group cardiac working group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25732174" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Cardiac troponin testing in idiopathic inflammatory myopathies and systemic sclerosis-spectrum disorders: biomarkers to distinguish between primary cardiac involvement and low-grade skeletal muscle disease activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35084310" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Troponin elevation independently associates with mortality in systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35808990" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Cardiovascular magnetic resonance in autoimmune rheumatic diseases: a clinical consensus document by the European Association of Cardiovascular Imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27509103" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Raynaud's Phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37582056" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Raynaud phenomenon and microvasculopathy in systemic sclerosis: multi-modality imaging for diagnosis and evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14677040" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Usefulness of technetium-99m tetrofosmin SPECT to detect abnormal myocardial perfusion in systemic lupus erythematosus or systemic sclerosis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11039455" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Thallium-201 myocardial SPET in patients with collagen disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31391176" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37354723" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Sudden cardiac death, arrhythmias and abnormal electrocardiography in systemic sclerosis: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8417518" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Cardiac and skeletal muscle disease in systemic sclerosis (scleroderma): a high risk association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/961700" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The cardiac conduction system in progressive systemic sclerosis. Clinical and pathologic features of 35 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5780367" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16935995" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14557344" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35387218" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Autonomic nervous system dysfunction correlates with microvascular damage in systemic sclerosis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35387218" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Autonomic nervous system dysfunction correlates with microvascular damage in systemic sclerosis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9227172" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Pericardial involvement in systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29967777" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Clinically Symptomatic Pericardial Effusions in Hospitalized Systemic Sclerosis Patients: Demographics and Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4279550" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Pericardial disease in scleroderma (systemic sclerosis).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25248336" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : European Association of Cardiovascular Imaging (EACVI) position paper: Multimodality imaging in pericardial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22239888" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Simultaneous right and left heart real-time, free-breathing CMR flow quantification identifies constrictive physiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36797018" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Cardiac involvement assessment in systemic sclerosis using speckle tracking echocardiography: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21538320" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Systemic sclerosis is an independent risk factor for increased coronary artery calcium deposition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6726049" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Restrictive cardiomyopathy in scleroderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19279015" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29352073" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Right Ventricular Myofilament Functional Differences in Humans With Systemic Sclerosis-Associated Versus Idiopathic Pulmonary Arterial Hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27169739" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Right Ventricular Functional Reserve in Pulmonary Arterial Hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23797369" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Right ventricular dysfunction in systemic sclerosis-associated pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10430758" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Asymmetry of right ventricular enlargement in response to tricuspid regurgitation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20620859" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20362924" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Assessment of myocardial mechanics using speckle tracking echocardiography: fundamentals and clinical applications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27266598" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Unique Abnormalities in Right Ventricular Longitudinal Strain in Systemic Sclerosis Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29167303" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Right ventricular longitudinal strain is diminished in systemic sclerosis compared with idiopathic pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33860914" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Assessment of right ventricular reserve utilizing exercise provocation in systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36243216" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Stress Echocardiographic Prediction of Emerging Pulmonary Vascular Disease in Systemic Sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35717399" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Defining minimal detectable difference in echocardiographic measures of right ventricular function in systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26360334" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31500448" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Validation of the Tricuspid Annular Plane Systolic Excursion/Systolic Pulmonary Artery Pressure Ratio for the Assessment of Right Ventricular-Arterial Coupling in Severe Pulmonary Hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36746368" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : The role of TAPSE/sPAP ratio in predicting pulmonary hypertension and mortality in the systemic sclerosis EUSTAR cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34605890" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : In systemic sclerosis, the TAPSE/sPAP ratio can be used in addition to the DETECT algorithm for pulmonary arterial hypertension diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37603839" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Acute cardiovascular complications of immune-mediated systemic inflammatory diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35482838" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Novel Approaches to Imaging the Pulmonary Vasculature and Right Heart.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25441329" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Echocardiographic prediction of pre- versus postcapillary pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17985401" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Cardiac magnetic resonance imaging detects subclinical right ventricular impairment in systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18946331" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Systemic sclerosis and cardiac dysfunction: evolving concepts and diagnostic methodologies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18061791" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : New clinical and ultrastructural findings in hydroxychloroquine-induced cardiomyopathy--a report of 2 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17959655" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20476869" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Successful control of scleroderma myocarditis using a combination of cyclophosphamide and methylprednisolone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29862463" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Immunomodulatory treatment for lymphocytic myocarditis-a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1723374" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Cyclophosphamide toxicity. Characterising and avoiding the problem.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35904231" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Stem cell transplantation for systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11277179" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Severe cardiac toxicity in hematological stem cell transplantation: predictive value of reduced left ventricular ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11041571" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Myopericarditis caused by cyclophosphamide used to mobilize peripheral blood stem cells in a myeloma patient with renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29777655" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Long-Term Outcomes in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry (PHAROS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21900368" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36173815" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Improved Survival for Patients with Systemic Sclerosis-associated Pulmonary Arterial Hypertension: The Johns Hopkins Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32113575" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Systemic sclerosis-associated interstitial lung disease.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
